European CHMP recommends approval of somapacitan (Sogroya) for treatment of growth hormone deficiency in adults

Somapacitan is a somatropin agonist that acts directly via the growth hormone‑receptor and/or indirectly via insulin-like growth factor‑I produced in tissues. It is intended to be licensed for the replacement of endogenous growth hormone.

European Medicines Agency